A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Treatment-Refractory Metastatic and Unresectable SCC of the Head and Neck

Trial Profile

A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Treatment-Refractory Metastatic and Unresectable SCC of the Head and Neck

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Tavokinogene telsaplasmid (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors OncoSec Medical
  • Most Recent Events

    • 12 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 16 Jun 2016 Preliminary findings from this trial were presented at the EUROGIN 2016 Conference, according to an OncoSec Medical media release.
    • 02 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top